The EZH2 and EZH1 inhibitor valemetostat derepresses p16INK4a to induce early endomitotic exit in megakaryocytes [scATAC-Seq]
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 66 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 66 samples: 58 distinct titles, 8 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE270684_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1127050 and SRA study SRP515426. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 66 sample titles: 58 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8350048 DMSO, TPO/FL/SCF, 10d, donor3, batch1
- GSM8350049 Val-110, TPO/FL/SCF, 10d, donor3, batch1
- GSM8350050 Val-330, TPO/FL/SCF, 10d, donor3, batch1
- GSM8350051 Val-1k, TPO/FL/SCF, 10d, donor3, batch1
- GSM8350052 DMSO, TPO/FL/SCF, 3d, donor3, batch1
- GSM8350053 Val-110, TPO/FL/SCF, 3d, donor3, batch1
- GSM8350054 Val-330, TPO/FL/SCF, 3d, donor3, batch1
- GSM8350055 Val-1k, TPO/FL/SCF, 3d, donor3, batch1
- GSM8350056 DMSO, TPO/FL/SCF, 7d, donor3, batch1
- GSM8350057 Val-110, TPO/FL/SCF, 7d, donor3, batch1
- GSM8350058 Val-330, TPO/FL/SCF, 7d, donor3, batch1
- GSM8350059 Val-1k, TPO/FL/SCF, 7d, donor3, batch1
- GSM8350060 DMSO, TPO, 7d, donor3, batch1
- GSM8350061 Val-330, TPO, 7d, donor3, batch1
- GSM8350062 Val-1k, TPO, 7d, donor3, batch1
- GSM8350063 No treatment, No cytokine, 0d, donor3, batch1
- GSM8350064 DMSO, TPO/FL/SCF, 14d, donor3, batch1
- GSM8350065 Val-330, TPO/FL/SCF, 14d, donor3, batch1
- GSM8350066 Val-1k, TPO/FL/SCF, 14d, donor3, batch1
- GSM8350067 DMSO, TPO, 14d, donor3, batch1
- GSM8350068 DMSO, IL3/IL6, 3d, donor1, batch2
- GSM8350069 DMSO, TPO/IL3/IL6, 3d, donor1, batch2
- GSM8350070 DMSO, TPO/FL/SCF/IL3/IL6, 3d, donor1, batch2
- GSM8350071 DMSO, TPO/FL/SCF, 3d, donor2, batch2
- GSM8350072 DMSO, IL3/IL6, 3d, donor2, batch2
- GSM8350073 DMSO, TPO/IL3/IL6, 3d, donor2, batch2
- GSM8350074 DMSO, TPO/FL/SCF/IL3/IL6, 3d, donor2, batch2
- GSM8350075 DMSO, TPO, 7d, donor1, batch2
- GSM8350076 Val-1k, TPO, 7d, donor1, batch2
- GSM8350077 DMSO, IL3/IL6, 7d, donor1, batch2
- GSM8350078 Val-1k, IL3/IL6, 7d, donor1, batch2
- GSM8350079 DMSO, TPO/IL3/IL6, 7d, donor1, batch2
- GSM8350080 Val-1k, TPO/IL3/IL6, 7d, donor1, batch2
- GSM8350081 DMSO, TPO/FL/SCF/IL3/IL6, 7d, donor1, batch2
- GSM8350082 Val-1k, TPO/FL/SCF/IL3/IL6, 7d, donor1, batch2
- GSM8350083 DMSO, TPO/FL/SCF, 7d, donor2, batch2
- GSM8350084 Val-1k, TPO/FL/SCF, 7d, donor2, batch2
- GSM8350085 DMSO, IL3/IL6, 7d, donor2, batch2
- GSM8350086 Val-1k, IL3/IL6, 7d, donor2, batch2
- GSM8350087 DMSO, TPO/IL3/IL6, 7d, donor2, batch2
+ 26 more — browse all 66 samples with per-sample file links →
- GSE285897 EZH1/EZH2 Inhibition Enhances Adoptive T-cell Immunotherapy Against Multiple Cancer Models 12 samples shares ezh2, ezh1
- GSE252382 ATACseq of TNBC cell lines treated with EZH2i (tazemetostat) and/or AKTi (ipatasertib) 84 samples shares ezh2
- GSE311098 CUT&RUN profiling of EZH2, H3K27me3, and H3K4me3 enrichment in FACS-sorted CD70⁻ and CD70⁺ tumor cells from untreated ex vivo ccRCC and HGSOC patient-derived xenografts. 82 samples shares ezh2
- GSE302321 Co-targeting EZH2 and TEAD elicits apoptosis through tumor-intrinsic innate immune signaling in Hippo pathway-mutated cancers - ChIP-seq data from genetic disruption of EZH2 41 samples shares ezh2
- GSE213248 Inhibiting EZH2 Targets Atypical Teratoid Rhabdoid Tumor by Triggering Viral Mimicry via Both RNA and DNA Sensing Pathways [CUT&RUN] 24 samples shares ezh2
- GSE294323 Thyroid cancer-associated EZH1 Q571R mutation drives chromatin compaction and H3K27me3 invasion into active chromatin 18 samples shares ezh1
- GSE193481 Super-silencer perturbation by EZH2 and REST inhibition leads to large loss of chromatin interactions and reduction in cancer growth [ChIP-seq] 18 samples shares ezh2
- GSE294321 Thyroid cancer-associated EZH1 Q571R mutation drives chromatin compaction and H3K27me3 invasion into active chromatin 16 samples shares ezh1
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.